Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | PDE6D | O43924 | 2/20 | 0.36 |
| ▸ | PDE6A | P16499 | 2/20 | 0.36 |
| ▸ | PDE6G | P18545 | 2/20 | 0.36 |
| ▸ | PDE6B | P35913 | 2/20 | 0.36 |
| ▸ | PDE6C | P51160 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13728317 | 0.86 | PDGFRB (0.46) | PDGFRBPDGFRAHTTMEN1KMT2A | |
| SCHEMBL15942810 | 0.80 | CYP1A2 (0.44) | PDGFRBPDGFRAHTTMEN1KMT2A | |
| SCHEMBL622678 | 0.80 | PDGFRB (0.48) | PDGFRBPDGFRAHTTMEN1KMT2A | |
| SCHEMBL17244314 | 0.79 | PDGFRB (0.40) | PDGFRBPDGFRAHTTMEN1KMT2A | |
| SCHEMBL622060 | 0.79 | PDGFRB (0.40) | PDGFRBPDGFRAHTTMEN1KMT2A | |
| SCHEMBL25113003 | 0.79 | EGFR (0.41) | PDGFRBPDGFRAHTTL3MBTL1NPC1 | |
| SCHEMBL622192 | 0.79 | PIK3CA (0.42) | PDGFRBPDGFRAHTTMEN1KMT2A | |
| SCHEMBL622358 | 0.79 | HPGD (0.41) | PDGFRBPDGFRAHTTNPC1RAB9A | |
| SCHEMBL13552130 | 0.76 | HTT (0.41) | PDGFRBPDGFRAHTTMEN1KMT2A | |
| SCHEMBL13554346 | 0.76 | CSF1R (0.41) | PDGFRBPDGFRAHTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044077-B1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| WO-2016123146-A1 | BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123146-A1 | BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-3050888-A1 | Compounds for the treatment of bacterial infections | Merck Sharp & Dohme Corp. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-3050888-A1 | Compounds for the treatment of bacterial infections | Merck Sharp & Dohme Corp. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20150336954-A1 | Process for Manufacturing a Naphthyridine Derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20150336954-A1 | Process for Manufacturing a Naphthyridine Derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20150336954-A1 | Process for Manufacturing a Naphthyridine Derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | disclosed |
| EP-2379554-B1 | NAPHTHYRIDIN-2(1H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| EP-2379554-B1 | NAPHTHYRIDIN-2(1H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| WO-2010081874-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081874-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| EP-2080761-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080761-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-07-22 | — | — | EP | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336954-A1 | Process for Manufacturing a Naphthyridine Derivative | NRDC, SBDS, CYP1B1 | PDGFRB 2423/4885PDGFRA 2165/4885HTT 3148/4885 |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | PDGFRB 4008/4885PDGFRA 3448/4885HTT 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.